Overview
Biopharmaceutical firm's Q4 total revenue grew 144% yr/yr to $168.4 mln
Net income for Q4 missed analyst expectations
Company to acquire Corstasis Therapeutics to expand cardiovascular franchise
Outlook
Esperion expects 2026 operating expenses between $225 mln and $255 mln
Result Drivers
U.S. PRODUCT REVENUE - Q4 U.S. net product revenue grew 38% y/y to $43.7 mln, driven by increased prescription growth and market access for bempedoic acid franchise
COLLABORATION REVENUE - Q4 collaboration revenue increased 232% y/y, driven by a $90 mln payment from Otsuka for regulatory approval and favorable NHI Price listing
GLOBAL EXPANSION - Esperion's global expansion strategy accelerated with regulatory approvals and market launches, contributing to revenue growth
Company press release: ID:nGNX1vGRQW
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Sales | $43.72 mln | ||
Q4 Net Income | Miss | $61.83 mln | $69.96 mln (7 Analysts) |
Q4 Operating Income | Miss | $85.23 mln | $98.67 mln (6 Analysts) |
Q4 Basic EPS | $0.26 | ||
Q4 Operating Expenses | $83.21 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.00, about 64.5% above its March 9 closing price of $3.04
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 144 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments